4 ml solución inyectable en jeringa precargada

A novel COMBinATorial therapy with albumin and enoxaparin in patients with decompensated cirrhosis at high-risk of poor outcome (COMBAT trial).

Phase III, randomized, open-label, single-site clinical trial to evaluate the efficacy and safety of enoxaparin as a prophylactic treatment for localized intravascular coagulopathy and the impact of endothelial damage markers in patients aged 0 to 18 years with slow-flow vascular malformations undergoing percutaneous interventional procedures (PEaRL-X)